PT2172211E - Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer - Google Patents

Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer Download PDF

Info

Publication number
PT2172211E
PT2172211E PT80173057T PT08017305T PT2172211E PT 2172211 E PT2172211 E PT 2172211E PT 80173057 T PT80173057 T PT 80173057T PT 08017305 T PT08017305 T PT 08017305T PT 2172211 E PT2172211 E PT 2172211E
Authority
PT
Portugal
Prior art keywords
cancer
glioblastom
gbm
tumor
types
Prior art date
Application number
PT80173057T
Other languages
English (en)
Portuguese (pt)
Inventor
Toni Weinschenk
Claudia Trautwein
Oliver Schoor
Norbert Hilf
Harpreet Singh
Steffen Walter
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of PT2172211E publication Critical patent/PT2172211E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
PT80173057T 2008-10-01 2008-10-01 Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer PT2172211E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20080017305 EP2172211B1 (en) 2008-10-01 2008-10-01 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers

Publications (1)

Publication Number Publication Date
PT2172211E true PT2172211E (pt) 2015-03-09

Family

ID=40342382

Family Applications (12)

Application Number Title Priority Date Filing Date
PT80173057T PT2172211E (pt) 2008-10-01 2008-10-01 Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer
PT80179211T PT2172212T (pt) 2008-10-01 2008-10-13 Nova imunoterapia contra vários tumores incluindo tumores neuronais e cerebrais
PT97787493T PT2331118T (pt) 2008-10-01 2009-09-28 Composição de peptídeos associados a tumores e vacina anticancro relacionada para tratamento do glioblastoma (gbm) e outros cancros¿
PT161792262T PT3120870T (pt) 2008-10-01 2009-09-28 Nova imunoterapia contra vários tumores incluindo tumores meuronais e cerebrais
PT161791637T PT3106175T (pt) 2008-10-01 2009-09-28 Nova imunoterapia contra vários tumores incluindo tumores meuronais e cerebrais
PT16179241T PT3111952T (pt) 2008-10-01 2009-09-28 Nova imunoterapia contra vários tumores incluindo tumores neuronais e cerebrais
PT161791926T PT3120869T (pt) 2008-10-01 2009-09-28 Nova imunoterapia contra vários tumores incluindo tumores meuronais e cerebrais
PT16165070T PT3069728T (pt) 2008-10-01 2009-09-28 Nova imunoterapia para vários tumores incluindo tumors neuronais e cerebrais
PT97787501T PT2341927T (pt) 2008-10-01 2009-09-28 Composição incluindo péptidos associados a tumores e uma vacina para o tratamento do glioblastoma e outros cancros
PT161791744T PT3120868T (pt) 2008-10-01 2009-09-28 Nova imunoterapia contra vários tumores incluindo tumores meuronais e cerebrais
PT161791694T PT3132801T (pt) 2008-10-01 2009-09-28 Nova imunoterapia contra vários tumores incluindo tumores neuronais e cerebrais
PT161792148T PT3124043T (pt) 2008-10-01 2009-09-28 Nova imunoterapia contra vários tumores incluindo tumores meuronais e cerebrais

Family Applications After (11)

Application Number Title Priority Date Filing Date
PT80179211T PT2172212T (pt) 2008-10-01 2008-10-13 Nova imunoterapia contra vários tumores incluindo tumores neuronais e cerebrais
PT97787493T PT2331118T (pt) 2008-10-01 2009-09-28 Composição de peptídeos associados a tumores e vacina anticancro relacionada para tratamento do glioblastoma (gbm) e outros cancros¿
PT161792262T PT3120870T (pt) 2008-10-01 2009-09-28 Nova imunoterapia contra vários tumores incluindo tumores meuronais e cerebrais
PT161791637T PT3106175T (pt) 2008-10-01 2009-09-28 Nova imunoterapia contra vários tumores incluindo tumores meuronais e cerebrais
PT16179241T PT3111952T (pt) 2008-10-01 2009-09-28 Nova imunoterapia contra vários tumores incluindo tumores neuronais e cerebrais
PT161791926T PT3120869T (pt) 2008-10-01 2009-09-28 Nova imunoterapia contra vários tumores incluindo tumores meuronais e cerebrais
PT16165070T PT3069728T (pt) 2008-10-01 2009-09-28 Nova imunoterapia para vários tumores incluindo tumors neuronais e cerebrais
PT97787501T PT2341927T (pt) 2008-10-01 2009-09-28 Composição incluindo péptidos associados a tumores e uma vacina para o tratamento do glioblastoma e outros cancros
PT161791744T PT3120868T (pt) 2008-10-01 2009-09-28 Nova imunoterapia contra vários tumores incluindo tumores meuronais e cerebrais
PT161791694T PT3132801T (pt) 2008-10-01 2009-09-28 Nova imunoterapia contra vários tumores incluindo tumores neuronais e cerebrais
PT161792148T PT3124043T (pt) 2008-10-01 2009-09-28 Nova imunoterapia contra vários tumores incluindo tumores meuronais e cerebrais

Country Status (24)

Country Link
US (19) US8318677B2 (enExample)
EP (12) EP2172211B1 (enExample)
JP (10) JP5753783B2 (enExample)
KR (6) KR102392070B1 (enExample)
CN (3) CN102170900B (enExample)
AU (2) AU2009300088B2 (enExample)
BR (2) BRPI0920791B8 (enExample)
CA (9) CA2936870C (enExample)
CY (11) CY1116302T1 (enExample)
DK (12) DK2172211T3 (enExample)
EA (3) EA032437B1 (enExample)
ES (12) ES2536465T3 (enExample)
HR (12) HRP20201025T8 (enExample)
HU (11) HUE031030T2 (enExample)
LT (10) LT2172212T (enExample)
MX (3) MX2011003540A (enExample)
NZ (4) NZ591882A (enExample)
PL (12) PL2172211T3 (enExample)
PT (12) PT2172211E (enExample)
RS (12) RS53782B1 (enExample)
SI (12) SI2172211T1 (enExample)
TR (2) TR201900852T4 (enExample)
UA (3) UA125277C2 (enExample)
WO (2) WO2010037514A2 (enExample)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435507B2 (en) 2004-08-19 2013-05-07 University Of Maryland Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
AU2008281015B2 (en) * 2007-07-27 2012-07-26 Immatics Biotechnologies Gmbh Novel immunotherapy against neuronal and brain tumors
SI2113253T1 (sl) 2008-04-30 2010-06-30 Immatics Biotechnologies Gmbh Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
PL2119726T5 (pl) 2008-05-14 2018-04-30 Immatics Biotechnologies Gmbh Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu
RS53782B1 (sr) 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
TW201124530A (en) * 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
SE535982C2 (sv) * 2009-12-15 2013-03-19 Theravac Pharmaceuticals Ab Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
AU2015200751B2 (en) * 2010-03-19 2016-11-10 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
DK2608799T3 (en) * 2010-08-24 2019-03-18 Univ Pittsburgh Commonwealth Sys Higher Education INTERLEUKIN 13-RECEPTOR-ALPHA 2-PEPTIDE-BASED BRAIN CANCER VACCINES
US20140017266A1 (en) * 2010-12-03 2014-01-16 The Government Of The United States, As Represented By The Secretary Of Hhs, Nih Anti-podoplanin antibodies and methods of use
KR20130126671A (ko) * 2010-12-14 2013-11-20 이매틱스 바이오테크놀로지스 게엠베하 전립선 관련 항원 분자로부터 유래된 hla 결합 펩티드 및 이의 사용방법
US20140154269A1 (en) * 2011-04-26 2014-06-05 The Methodist Hospital Research Institute Targeted nanovectors and their use for treatment of brain tumors
CN104023749B (zh) 2011-09-14 2019-12-17 西北大学 能穿过血脑屏障的纳米缀合物
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
CN110711188A (zh) 2012-01-20 2020-01-21 德玛公司 经取代的己糖醇类用于治疗恶性肿瘤的用途
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CN103372217B (zh) * 2012-04-28 2014-12-10 中国科学院深圳先进技术研究院 聚合物纳米载体制剂及其制备方法和应用
EP2849772A4 (en) * 2012-05-16 2016-03-02 Stemline Therapeutics Inc TUMOR VACCINES TREATED AGAINST CANCER STEM CELLS
CN112587658A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
TWI636065B (zh) * 2013-08-05 2018-09-21 伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
PT3456339T (pt) 2013-08-05 2021-12-09 Immatics Biotechnologies Gmbh Nova imunoterapia contra vários tumores, tais como cancro do pulmão, incluindo cpnpc
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
MX2019013161A (es) * 2013-11-04 2020-02-03 Immatics Biotechnologies Gmbh Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales.
CN104698059B (zh) * 2013-12-04 2017-07-21 苏州中赢医疗科技有限公司 一种脑胶质瘤肿瘤标志物及其应用
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
RS60106B1 (sr) 2014-04-25 2020-05-29 Bluebird Bio Inc Mnd promoterni himerni antigenski receptori
EP3134095B1 (en) 2014-04-25 2020-04-22 Bluebird Bio, Inc. Improved methods for manufacturing adoptive cell therapies
JP6613526B2 (ja) * 2014-05-28 2019-12-04 学校法人東京女子医科大学 膠芽腫の予測方法
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
CN111394317B (zh) 2014-06-06 2024-07-12 2赛文缇生物公司 改善的t细胞组合物
JP6366379B2 (ja) * 2014-06-20 2018-08-01 キヤノン株式会社 被検体情報取得装置
US20170226216A1 (en) 2014-07-24 2017-08-10 Bluebird Bio, Inc. Bcma chimeric antigen receptors
JP6474893B2 (ja) * 2014-11-06 2019-02-27 オーエスイー・イミュノセラピューティクス 脳転移の処置のための治療用マルチペプチドｔ特異的免疫療法
SG10202013144UA (en) 2014-12-12 2021-02-25 Bluebird Bio Inc Bcma chimeric antigen receptors
KR102435015B1 (ko) * 2014-12-23 2022-08-22 이매틱스 바이오테크놀로지스 게엠베하 간세포 암종(hcc) 및 기타 암들에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
KR20240151873A (ko) 2015-03-17 2024-10-18 이매틱스 바이오테크놀로지스 게엠베하 췌장암 및 기타 암에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
CN107810193B (zh) * 2015-05-06 2022-03-22 伊玛提克斯生物技术有限公司 用于结直肠癌(crc)和其他癌症免疫治疗的新型肽和肽组合物及其支架
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
EP3307307A4 (en) 2015-06-09 2019-05-01 The Board of Regents of the University of Oklahoma COMPOSITIONS AND TREATMENTS FOR HAEMOPHILUS INFLUENZAE
US11207405B2 (en) 2015-06-24 2021-12-28 Immodulon Therapeutics Limited Checkpoint inhibitor and a whole cell Mycobacterium for use in cancer therapy
CN108026154B (zh) 2015-07-01 2022-03-08 伊玛提克斯生物技术有限公司 用于卵巢癌和其他癌症免疫治疗的新型肽和肽组合物
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
PE20180259A1 (es) * 2015-07-06 2018-02-05 Immatics Biotechnologies Gmbh Nuevos peptidos y combinacion de peptidos para usar en inmunoterapia contra el cancer esofagico y otros canceres
MY189596A (en) * 2015-07-15 2022-02-18 Immatics Biotechnologies Gmbh A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
TWI794761B (zh) 2015-08-28 2023-03-01 德商英麥提克生物技術股份有限公司 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
WO2017040885A1 (en) 2015-09-03 2017-03-09 The Board Of Regents Of The University Of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
CN108289909A (zh) 2015-10-19 2018-07-17 巴尔的摩马里兰大学 用于产生工程改造的人原代血液树突细胞系的方法
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
HK1255541A1 (zh) * 2015-12-11 2019-08-23 Immatics Biotechnologies Gmbh 用於多种癌症免疫治疗的新型肽和肽组合物
SG11201804957VA (en) 2015-12-16 2018-07-30 Gritstone Oncology Inc Neoantigen identification, manufacture, and use
US10604759B2 (en) 2016-01-15 2020-03-31 City Of Hope Targeting glioblastoma stem cells through the TLX-TET3 axis
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en) * 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
CN105664134B (zh) * 2016-03-13 2019-04-26 浙江药苑生物科技有限公司 一种用于治疗骨癌的药物组合物
GB201604490D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
HUE060725T2 (hu) 2016-03-16 2023-04-28 Immatics Biotechnologies Gmbh Transzfektált T-sejtek és T-sejt receptorok daganatok ellen alkalmazott immunterápiában történõ használatra
GB201604494D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
SG10202110335PA (en) * 2016-04-06 2021-10-28 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
KR101881300B1 (ko) 2016-06-30 2018-07-25 영남대학교 산학협력단 아조피라졸 화합물 및 은 촉매 반응을 이용한 이의 신규한 합성방법
CN110022889B (zh) * 2016-10-03 2024-05-10 渥太华医院研究所 用于提高溶瘤rna病毒的生长、传播和溶瘤与免疫治疗效果的组合物和方法
US12109234B2 (en) 2016-11-04 2024-10-08 2Seventy Bio, Inc. Anti-BCMA CAR T cell compositions
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
MX2019007611A (es) 2016-12-22 2020-07-29 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
RU2725811C1 (ru) 2017-01-06 2020-07-06 Ютайлекс Ко., Лтд. Антитела против 4-1bb человека и их применение
GB201702863D0 (en) * 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
US20180248175A1 (en) * 2017-02-28 2018-08-30 Lyten, Inc. Mixed allotrope particulate carbon films and carbon fiber mats
CA3062591A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
CN107058596A (zh) * 2017-06-19 2017-08-18 上海市第十人民医院 一种与恶性胶质瘤诊断相关的标志物及其应用
CN107034305A (zh) * 2017-06-19 2017-08-11 上海市第十人民医院 恶性胶质瘤的一种诊断标志物
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
KR20200090855A (ko) 2017-11-22 2020-07-29 그릿스톤 온콜로지, 인코포레이티드 신생항원에 대한 접합 에피토프 제시 감소
EP3724327A4 (en) * 2017-12-14 2022-01-12 EZY Biotech LLC SUBJECT-SPECIFIC TUMOR INHIBITION CELLS AND THEIR USE
KR20220066413A (ko) 2017-12-14 2022-05-24 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
ES2935702T3 (es) * 2018-04-11 2023-03-09 Enterome S A Péptidos antigénicos para la prevención y el tratamiento del cáncer
CN108715832B (zh) * 2018-06-01 2020-11-10 段海峰 一种抑制肿瘤生长的间充质干细胞及制备方法和应用
JP2021530218A (ja) 2018-07-11 2021-11-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. 血液脳関門を超える薬剤の送達のための方法および組成物
WO2020110154A1 (en) * 2018-11-30 2020-06-04 Bharat Biotech International Limited A chimeric therapeutic vaccine
RU2706554C1 (ru) * 2018-12-13 2019-11-19 Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ Способ создания противоинфекционной иммунологической защиты к Salmonella typhimurium и Listeria monocytogenes с помощью трансгенеза Т-лимфоцитов
CN109796536B (zh) * 2019-02-22 2021-09-17 上海尚泰生物技术有限公司 一种靶向胶质母细胞瘤多种抗原表位的ctl的制备方法
AR118519A1 (es) 2019-03-29 2021-10-20 Intervet Int Bv Estabilización de la bacteria mollicutes viva en una composición líquida
EP4600650A3 (en) 2019-04-05 2025-11-26 Earli Inc. Improved methods and compositions for synthetic biomarkers
US10937541B2 (en) * 2019-05-28 2021-03-02 PAIGE.AI, Inc. Systems and methods for processing images to prepare slides for processed images for digital pathology
JP7457733B2 (ja) 2019-05-30 2024-03-28 グリットストーン バイオ インコーポレイテッド 改変アデノウイルス
CN110579457B (zh) * 2019-09-20 2021-11-02 郑州大学第一附属医院 波形蛋白特异响应性荧光探针及其制备方法和应用
CN112824427B (zh) * 2019-11-18 2022-06-24 杨小骏 一种抑制胶质瘤的短肽及其应用
IL294608A (en) * 2020-01-10 2022-09-01 Brigham & Womens Hospital Inc Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer
CN115151268A (zh) * 2020-02-24 2022-10-04 加利福尼亚大学董事会 使用脑特异性抗原归巢，阻断和向大脑提供基于细胞的治疗
CN113318225B (zh) * 2020-02-28 2024-01-19 无锡派列博生物医药科技有限公司 肿瘤免疫增强剂及其制法和应用
CN113621025A (zh) * 2020-03-18 2021-11-09 北京鼎成肽源生物技术有限公司 一种乳腺癌靶标抗原、乳腺癌靶标抗原刺激培养的ctl细胞及其应用
EP4127188A4 (en) 2020-03-31 2024-08-21 Walking Fish Therapeutics MODIFIED B CELLS AND METHODS OF USE THEREOF
IL296947A (en) * 2020-03-31 2022-12-01 Walking Fish Therapeutics Modified b cells and methods of use thereof
MX2022013208A (es) 2020-05-12 2022-11-14 Cue Biopharma Inc Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
CA3187258A1 (en) 2020-08-06 2022-02-10 Karin Jooss Multiepitope vaccine cassettes
KR102711471B1 (ko) 2020-08-14 2024-09-30 서울대학교산학협력단 B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물
EP4203994A4 (en) * 2020-08-28 2024-07-03 Torigen Pharmaceuticals, Inc. Immune memory enhanced preparations and uses thereof
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
WO2022192457A1 (en) * 2021-03-09 2022-09-15 Bostongene Corporation Predicting response to treatments in patients with clear cell renal cell carcinoma
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
WO2023192820A2 (en) * 2022-03-30 2023-10-05 Iogenetics, Llc Tumor-associated antigens in brain tumors
PL441229A1 (pl) * 2022-05-19 2023-11-20 Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych
CN120272531B (zh) * 2025-06-10 2025-08-19 鼐济医药科技(杭州)有限公司 一种基于aav介导免疫微环境的脑胶质瘤动物模型构建方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IE53176B1 (en) 1978-12-22 1988-08-17 Biogen Nv Recombinant dna molecules and their method of production
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US5338839A (en) * 1988-04-12 1994-08-16 Massachusetts Institute Of Technology DNA encoding nestin protein
GB2267257A (en) 1992-05-14 1993-12-01 Ford Motor Co A vehicle load compartment liner.
KR100235089B1 (en) 1992-05-14 1999-12-15 Mitsui Chemicals Inc Ptp or blister packaging articles and packaging material therefor
AU6852594A (en) 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US6805861B2 (en) 1996-01-17 2004-10-19 Imperial College Innovations Limited Immunotherapy using cytotoxic T lymphocytes (CTL)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
IL120561A0 (en) * 1996-04-24 1997-07-13 Akzo Nobel Nv Peptides suitable for use in immunosuppressive therapy
EP0942748A4 (en) * 1996-07-22 2004-12-08 Univ Rockefeller ENV-GLYCOPROTEIN VACCINE FOR PROTECTION AGAINST HTLV-I AND HTLV-II INFECTIONS
WO1998031797A1 (en) 1997-01-15 1998-07-23 Zymogenetics, Inc. Zppar6, human tailless nuclear hormone receptor (tlx receptor)
EP0910641A1 (en) * 1997-02-13 1999-04-28 Smithkline Beecham Plc Neural cell adhesion molecule splicing variants
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1999028349A2 (en) * 1997-12-02 1999-06-10 Medarex, Inc. CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS
US7258860B2 (en) * 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20070004655A9 (en) * 1998-04-27 2007-01-04 Murphy Gerald P Nr-cam gene, nucleic acids and nucleic acid products for therapeutic and diagnostic uses for tumors
US20030082586A1 (en) * 1999-06-29 2003-05-01 Millennium Pharmaceuticals, Inc. Antibodies having diagnostic, preventive, therapeutic, and other uses
CA2392757A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences Inc. Nucleic acids, proteins, and antibodies
US20030139327A9 (en) * 2000-01-31 2003-07-24 Rosen Craig A. Nucleic acids, proteins, and antibodies
AU785493B2 (en) 2000-03-27 2008-01-03 Technion Research & Development Foundation Ltd. Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
WO2002020036A1 (de) * 2000-09-06 2002-03-14 Mueller Friederike Arzneimittel mit einer für das rna-bindende koc-protein kodierenden dna-sequenz, einem koc-protein oder einer dna-sequenz des koc-promotors
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
AU2002226030A1 (en) * 2000-12-04 2002-06-18 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
WO2002046767A2 (en) * 2000-12-08 2002-06-13 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease
AU2002254482A1 (en) * 2001-03-19 2002-10-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
CA2364106A1 (fr) * 2001-11-30 2003-05-30 Christopher Gillberg Polynucleotide et proteine impliques dans la synaptogenese, variants de ceux-ci, et leurs applications therapeutiques et diagnostiques
US6589642B1 (en) 2001-12-21 2003-07-08 Kloeckner Pentaplast Of America, Inc. Three part high moisture barrier for packages
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US6992176B2 (en) * 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20030223994A1 (en) 2002-02-20 2003-12-04 Hoogenboom Henricus Renerus Jacobus Mattheus MHC-peptide complex binding ligands
AU2003258134A1 (en) * 2002-08-09 2004-02-25 Applera Corporation Lung cancer target proteins and use thereof
JP4721633B2 (ja) * 2002-10-11 2011-07-13 財団法人癌研究会 血小板凝集促進活性を有する物質
WO2004067029A1 (fr) * 2002-12-27 2004-08-12 Shenzhen Tsinghua Yuanxing Bio-Pharm Science & Technology Co., Ltd. Procede de preparation d'un vaccin et vaccins antitumoraux
JP2006522156A (ja) 2003-04-04 2006-09-28 ファーマサイクリックス，インコーポレイテッド サフィリンおよびその使用
US7273980B2 (en) 2004-01-13 2007-09-25 Wardle Scott A Position and velocity transducer using a phonograph disc and turntable
CA2554195C (en) * 2004-01-23 2011-02-22 Green Peptide Co., Ltd. Peptide originating in epidermal growth factor receptor (egfr)
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US20080280317A1 (en) * 2004-08-27 2008-11-13 Northeastern University Comprehensive Characterization Of Complex Proteins At Trace Levels
SI1642905T1 (sl) * 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Imunogeni T-pomagalni epitop iz humanega tumornega antigena in imunoterapevtski postopki, ki uporabljajo navedeni epitop
WO2006062094A1 (ja) * 2004-12-07 2006-06-15 Toray Industries, Inc. 新規癌抗原ペプチド及びその用途
KR100809410B1 (ko) * 2005-07-06 2008-03-05 주식회사 브레인가드 줄기세포 분화 유도용 조성물 및 그의 용도
PL1760089T3 (pl) * 2005-09-05 2010-03-31 Immatics Biotechnologies Gmbh Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa
ATE461215T1 (de) 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
WO2007047796A2 (en) 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
WO2007072494A1 (en) 2005-12-23 2007-06-28 Naik Praful Ramchandra Metallized packaging blister container
CA2665816C (en) * 2006-09-21 2016-07-12 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
CA2700573C (en) * 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008109757A2 (en) * 2007-03-06 2008-09-12 Iterative Therapeutics, Inc. Methods and compositions involving polymeric immunoglobulin fusion proteins
US8747855B2 (en) * 2008-04-09 2014-06-10 Technion Research & Development Foundation Limited Anti human immunodeficiency antibodies and uses thereof
KR101184869B1 (ko) 2008-04-24 2012-09-20 이매틱스 바이오테크놀로지스 게엠베하 백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형
SI2113253T1 (sl) * 2008-04-30 2010-06-30 Immatics Biotechnologies Gmbh Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
RS53782B1 (sr) 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
KR102311038B1 (ko) * 2014-05-28 2021-10-07 노노 인코포레이티드 Tat-nr2b9c의 클로라이드 염
PE20181897A1 (es) 2016-04-21 2018-12-11 Immatics Biotechnologies Gmbh Inmunoterapia contra el melanoma y otros tipos de cancer
EP3679065A4 (en) * 2017-09-06 2021-05-19 California Institute of Technology SIGNALING AND ANTIGEN-PRESENTING BIFUNCTIONAL RECEPTORS (SABR)

Also Published As

Publication number Publication date
DK3120868T3 (da) 2020-06-22
PL2341927T3 (pl) 2016-11-30
CN106986919A (zh) 2017-07-28
ES2819244T3 (es) 2021-04-15
EP3069728B1 (en) 2018-11-14
RS58443B1 (sr) 2019-04-30
RS55531B1 (sr) 2017-05-31
CY1123113T1 (el) 2021-10-29
EP2172211B1 (en) 2014-12-03
CA2936887A1 (en) 2010-04-08
CN102170900A (zh) 2011-08-31
PT3132801T (pt) 2020-02-04
LT3120869T (lt) 2020-11-10
SI2341927T1 (sl) 2016-08-31
UA125277C2 (uk) 2022-02-16
HK1161106A1 (en) 2012-08-24
US20120141517A1 (en) 2012-06-07
EP3120869A1 (en) 2017-01-25
CN102170900B (zh) 2016-10-26
DK3124043T3 (da) 2020-05-04
PL3111952T3 (pl) 2019-04-30
PL2172211T3 (pl) 2015-05-29
EP3111952A1 (en) 2017-01-04
RS55043B1 (sr) 2016-12-30
KR101687840B1 (ko) 2016-12-19
DK2331118T3 (da) 2017-01-09
ES2802227T3 (es) 2021-01-18
JP2017018101A (ja) 2017-01-26
EA201100586A1 (ru) 2011-10-31
US8961985B2 (en) 2015-02-24
LT3120870T (lt) 2020-08-10
SI2172211T1 (sl) 2015-03-31
CA2936869A1 (en) 2010-04-08
DK3069728T3 (en) 2019-02-25
EP2172212A3 (en) 2010-04-14
HRP20201015T8 (hr) 2022-01-21
EP3106175A1 (en) 2016-12-21
CA2936920A1 (en) 2010-04-08
TR201900852T4 (tr) 2019-02-21
PT3120869T (pt) 2020-09-22
US20160376314A1 (en) 2016-12-29
HRP20190202T1 (hr) 2019-03-22
CA2936869C (en) 2019-08-06
HRP20150223T8 (hr) 2015-07-03
HUE042115T2 (hu) 2019-06-28
KR20220058655A (ko) 2022-05-09
LT3124043T (lt) 2020-07-10
US20160376312A1 (en) 2016-12-29
EP2172212A2 (en) 2010-04-07
JP2017023136A (ja) 2017-02-02
US20160376317A1 (en) 2016-12-29
DK2172211T3 (en) 2015-02-16
ES2804723T3 (es) 2021-02-09
CY1119744T1 (el) 2018-06-27
HRP20160915T1 (hr) 2016-10-07
LT2172212T (lt) 2016-11-10
DK3111952T3 (en) 2019-01-28
US20160355550A1 (en) 2016-12-08
RS60338B1 (sr) 2020-07-31
LT3069728T (lt) 2019-02-11
HRP20201025T8 (hr) 2022-01-07
PT3069728T (pt) 2019-02-13
US10919931B2 (en) 2021-02-16
EP2172211A1 (en) 2010-04-07
KR20200085381A (ko) 2020-07-14
KR102392070B1 (ko) 2022-04-29
LT3106175T (lt) 2020-08-10
CA2936868A1 (en) 2010-04-08
ES2788129T8 (es) 2020-11-04
HUE051030T2 (hu) 2021-01-28
EP3120870B1 (en) 2020-04-01
RS55543B1 (sr) 2017-05-31
US10100085B2 (en) 2018-10-16
US20110002963A1 (en) 2011-01-06
CN102170901B (zh) 2015-01-07
EP3132801B1 (en) 2019-10-30
SI2172212T1 (sl) 2016-12-30
KR20110074894A (ko) 2011-07-04
CA2936924A1 (en) 2010-04-08
TR201900809T4 (tr) 2019-02-21
JP6294914B2 (ja) 2018-03-14
US8119139B2 (en) 2012-02-21
US10227381B2 (en) 2019-03-12
US8653035B2 (en) 2014-02-18
PL3069728T3 (pl) 2019-05-31
PL3120869T3 (pl) 2021-01-25
NZ624533A (en) 2015-09-25
CA2936924C (en) 2019-07-16
BRPI0920791B8 (pt) 2022-02-15
EP3106175B1 (en) 2020-04-01
US20150125478A1 (en) 2015-05-07
EP3132801A1 (en) 2017-02-22
EP2331118B1 (en) 2016-10-26
CA2936982C (en) 2019-12-03
SI3069728T1 (sl) 2019-03-29
RS60385B1 (sr) 2020-07-31
JP2016145210A (ja) 2016-08-12
HUE047365T2 (hu) 2020-04-28
CY1116302T1 (el) 2017-02-08
HRP20200722T1 (hr) 2020-10-16
BRPI0920791A2 (pt) 2019-12-10
NZ591882A (en) 2012-12-21
US20160376316A1 (en) 2016-12-29
NZ591855A (en) 2012-11-30
CA2739384A1 (en) 2010-04-08
PL2331118T3 (pl) 2017-05-31
PT2341927T (pt) 2016-08-02
ES2607460T3 (es) 2017-03-31
US12221493B2 (en) 2025-02-11
CA2936868C (en) 2019-10-22
PL3106175T3 (pl) 2020-08-24
EP2341927B1 (en) 2016-05-04
CY1123526T1 (el) 2022-03-24
JP6150859B2 (ja) 2017-06-21
HRP20170115T1 (hr) 2017-03-24
AU2009300088A1 (en) 2010-04-08
KR101883426B1 (ko) 2018-07-31
MX338294B (es) 2016-04-11
SI3120870T1 (sl) 2020-08-31
HRP20201228T1 (hr) 2021-02-05
KR102133402B1 (ko) 2020-07-14
US20210261614A1 (en) 2021-08-26
JP2014239681A (ja) 2014-12-25
LT3132801T (lt) 2020-02-10
JP6297632B2 (ja) 2018-03-20
RS60006B1 (sr) 2020-04-30
RS60656B1 (sr) 2020-09-30
HRP20200988T1 (hr) 2020-10-16
ES2770090T3 (es) 2020-06-30
EA201401104A1 (ru) 2015-05-29
DK2172212T3 (da) 2016-12-19
SI3111952T1 (sl) 2019-01-31
PT3124043T (pt) 2020-05-12
PL3120870T3 (pl) 2020-07-27
HRP20200110T1 (hr) 2020-05-15
CY1122913T1 (el) 2021-10-29
CA2739387C (en) 2019-10-29
US10906936B2 (en) 2021-02-02
DK3120869T3 (da) 2020-08-10
US20210253637A1 (en) 2021-08-19
EA023013B1 (ru) 2016-04-29
CY1121098T1 (el) 2019-12-11
JP2016047825A (ja) 2016-04-07
CA2936870C (en) 2019-11-26
US12234298B2 (en) 2025-02-25
KR101756488B1 (ko) 2017-07-11
HUE049366T2 (hu) 2020-09-28
CA2936870A1 (en) 2010-04-08
MX2011003539A (es) 2011-06-20
PL2172212T3 (pl) 2017-04-28
EP3120869B1 (en) 2020-07-22
HUE030296T2 (en) 2017-04-28
SI3120868T1 (sl) 2020-08-31
NZ603016A (en) 2014-05-30
PT3111952T (pt) 2019-02-05
AU2009300087B2 (en) 2014-09-04
EP3124043A1 (en) 2017-02-01
JP5855940B2 (ja) 2016-02-09
HUE041446T2 (hu) 2019-05-28
ES2584245T3 (es) 2016-09-26
US20100158931A1 (en) 2010-06-24
SI2331118T1 (sl) 2017-01-31
RS58229B1 (sr) 2019-03-29
US20160376313A1 (en) 2016-12-29
JP6294913B2 (ja) 2018-03-14
DK3120870T3 (da) 2020-06-22
CA2739387A1 (en) 2010-04-08
PT3120868T (pt) 2020-07-16
ES2708654T3 (es) 2019-04-10
EP3069728A1 (en) 2016-09-21
LT3120868T (lt) 2020-08-10
PT3106175T (pt) 2020-07-01
HUE049364T2 (hu) 2020-09-28
EP2341927A2 (en) 2011-07-13
HUE031030T2 (en) 2017-06-28
HRP20182151T1 (hr) 2019-02-08
CA2936887C (en) 2019-11-12
JP6214066B2 (ja) 2017-10-18
HUE049367T2 (hu) 2020-09-28
HUE050428T2 (hu) 2020-12-28
JP5883476B2 (ja) 2016-03-15
SI3106175T1 (sl) 2020-08-31
US20210347822A1 (en) 2021-11-11
US20210238227A1 (en) 2021-08-05
JP2012504563A (ja) 2012-02-23
UA103202C2 (ru) 2013-09-25
ES2788129T3 (es) 2020-10-20
HRP20201025T1 (hr) 2020-12-25
AU2009300087A1 (en) 2010-04-08
US11136352B2 (en) 2021-10-05
US20190010190A1 (en) 2019-01-10
WO2010037513A1 (en) 2010-04-08
US20130309193A1 (en) 2013-11-21
US10941181B2 (en) 2021-03-09
BRPI0920759A2 (pt) 2016-03-08
US8318677B2 (en) 2012-11-27
EP3120868A1 (en) 2017-01-25
RS53782B1 (sr) 2015-06-30
KR20180088494A (ko) 2018-08-03
SI3124043T1 (sl) 2020-07-31
RS60381B1 (sr) 2020-07-31
US20130004456A1 (en) 2013-01-03
EP2172212B1 (en) 2016-10-05
LT3111952T (lt) 2018-12-27
ES2536465T3 (es) 2015-05-25
ES2612466T3 (es) 2017-05-17
DK3132801T3 (da) 2020-02-10
CN102170901A (zh) 2011-08-31
EP3111952B1 (en) 2018-10-31
EA023378B1 (ru) 2016-05-31
EA201100587A1 (ru) 2011-10-31
HRP20150223T1 (hr) 2015-06-05
US20170326217A1 (en) 2017-11-16
ES2710608T3 (es) 2019-04-26
DK3106175T3 (da) 2020-06-22
JP5753783B2 (ja) 2015-07-22
KR20110082155A (ko) 2011-07-18
BRPI0920791B1 (pt) 2022-01-18
DK2331118T5 (en) 2017-06-19
ES2802226T3 (es) 2021-01-18
SI3132801T1 (sl) 2020-03-31
WO2010037514A3 (en) 2010-06-03
US10046037B2 (en) 2018-08-14
US10047123B2 (en) 2018-08-14
US10047124B2 (en) 2018-08-14
UA110599C2 (uk) 2016-01-25
US9993540B2 (en) 2018-06-12
HRP20161504T1 (hr) 2016-12-30
CA2936982A1 (en) 2010-04-08
PL3132801T3 (pl) 2020-06-15
EP2331118A1 (en) 2011-06-15
US20160376315A1 (en) 2016-12-29
WO2010037514A2 (en) 2010-04-08
PT3120870T (pt) 2020-07-01
EP3120870A1 (en) 2017-01-25
US11208434B2 (en) 2021-12-28
US8895514B2 (en) 2014-11-25
PT2331118T (pt) 2017-02-06
LT2331118T (lt) 2016-12-27
EP3120868B1 (en) 2020-04-08
HK1159526A1 (zh) 2012-08-03
CY1123089T1 (el) 2021-10-29
RS60386B1 (sr) 2020-07-31
JP2017029135A (ja) 2017-02-09
JP6367266B2 (ja) 2018-08-01
AU2009300088B2 (en) 2014-09-04
SI3120869T1 (sl) 2020-10-30
HUE029360T2 (en) 2017-02-28
JP2017018102A (ja) 2017-01-26
EA032437B1 (ru) 2019-05-31
PT2172212T (pt) 2016-12-22
JP2017000148A (ja) 2017-01-05
HRP20201015T1 (hr) 2020-10-16
CA2936920C (en) 2019-12-03
PL3120868T3 (pl) 2020-08-24
DK2341927T3 (en) 2016-08-15
CY1122677T1 (el) 2021-03-12
JP2012504393A (ja) 2012-02-23
CY1123098T1 (el) 2021-10-29
KR20160103558A (ko) 2016-09-01
MX2011003540A (es) 2011-06-20
CY1121258T1 (el) 2020-05-29
CY1118702T1 (el) 2017-07-12
CA2739384C (en) 2017-05-02
EP3124043B1 (en) 2020-04-29
PL3124043T3 (pl) 2020-07-27

Similar Documents

Publication Publication Date Title
PT2172211E (pt) Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer
IL283459B (en) Novel lipids and compositions for the delivery of therapeutics
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
DK2274032T3 (da) Anordning til medicinindgivelse
PL2567707T3 (pl) Kompozycja peptydów związanych z guzem i pokrewna szczepionka przeciw rakowi
BRPI0807544A2 (pt) Sólido farmacêutico e dose de vacina
DK3434687T3 (da) Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende samme
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
BRPI0919466A2 (pt) composição farmacêutica para liberação modificada
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
DK2173407T3 (da) Anordning til indgivelse af lægemiddel
BRPI0918971A2 (pt) tienopirimidinas para composições farmacêuticas
DK2274030T4 (da) Lægemiddelafgivelsesanordning
BRPI1008598A2 (pt) composição farmacêutica para inalação
DK2154971T3 (da) Synergistisk farmaceutisk kombination til behandling af cancer
BR112014005091A2 (pt) composição farmacêutica para o tratamento do câncer compreendendo conjugado de interferon alfa
BRPI0809661A2 (pt) Composição farmacêutica estabilizada contendo pregabalina
PT2632452T (pt) Compostos e composições para o tratamento do cancro
BRPI1005433A2 (pt) preparações farmacêuticas transdérmicas
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer
DK2285413T3 (da) Farmaceutisk sammensætning
SMT201700056B (it) Fosfaplatine e relativo utilizzo per il trattamento di cancro
BRPI1007484A2 (pt) composição farmacêutica para administração oral
BR112015012877A2 (pt) composto de fórmula, composição farmacêutica, uso do composto e método para o tratamento do câncer
BRPI0917562A2 (pt) composições farmacêuticas e métodos para estabilizar as mesmas